Canada markets closed
  • S&P/TSX

    19,228.03
    -0.87 (-0.00%)
     
  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     
  • DOW

    33,800.60
    +297.00 (+0.89%)
     
  • CAD/USD

    0.7985
    +0.0024 (+0.30%)
     
  • CRUDE OIL

    59.34
    -0.26 (-0.44%)
     
  • BTC-CAD

    75,246.95
    -587.28 (-0.77%)
     
  • CMC Crypto 200

    1,235.89
    +8.35 (+0.68%)
     
  • GOLD FUTURES

    1,744.10
    -14.10 (-0.80%)
     
  • RUSSELL 2000

    2,243.47
    +0.87 (+0.04%)
     
  • 10-Yr Bond

    1.6660
    +0.0340 (+2.08%)
     
  • NASDAQ

    13,900.19
    +70.89 (+0.51%)
     
  • VOLATILITY

    16.69
    -0.26 (-1.53%)
     
  • FTSE

    6,915.75
    -26.47 (-0.38%)
     
  • NIKKEI 225

    29,768.06
    +59.06 (+0.20%)
     
  • CAD/EUR

    0.6703
    +0.0026 (+0.39%)
     

Certara Reports Preliminary Fourth Quarter and Full Year 2020 Results and Issues Full Year 2021 Guidance

  • Oops!
    Something went wrong.
    Please try again later.
·22 min read
  • Oops!
    Something went wrong.
    Please try again later.

Year-over-year 2020 revenue grew 17% to $243.5 million

Raised $768.5 million in gross IPO proceeds for the Company and selling stockholders

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its preliminary results for the fourth quarter and full year ended December 31, 2020.

Highlights:

  • Revenue was $64.6 million in the fourth quarter of 2020, and $243.5 million for the full year, representing year-over-year growth of 20% and 17%.

  • Reported net loss was ($54.4) million in the fourth quarter of 2020, and ($49.4) million for the full year 2020, representing a year-over-year increase of net loss.

  • Adjusted EBITDA was $22.2 million in the fourth quarter of 2020, and $87.9 million for the full year, representing year-over-year growth of 36% and 28%.

  • Certara completed an initial public offering of 14.6 million shares, raising $316.3 million in net proceeds to the Company.

  • Certara issues 2021 revenue guidance of $272 million - $285 million, and Adjusted EBITDA guidance of $98 million - $102 million.

"Certara had another year of strong financial performance in 2020 with continued robust adoption of our end-to-end platform. Our dedicated Certara team achieved record full year revenue despite the challenges of the COVID-19 pandemic, delivering 17% growth in revenue and 18% growth in operating cash flow," said William F. Feehery, chief executive officer. "We successfully completed our IPO in December and are now better positioned to execute on our mission to accelerate the drug development process using our biosimulation software and technology-enabled services."

Fourth Quarter 2020 Results

"In the fourth quarter, our team remained focused on execution, delivering strong revenue growth and improved profitability. The financial performance, combined with the successful completion of our IPO, has strengthened our balance sheet and positioned the company for future growth," said Andrew Schemick, chief financial officer.

Total revenue for the fourth quarter of 2020 was $64.6 million, representing year-over-year growth of 20%. The revenue growth was driven primarily by technology enabled services and subscription software.

Total cost of revenue for the fourth quarter of 2020 was $34.9 million, an increase from $22.0 million in the fourth quarter of 2019, primarily due to an $8.5 million increase in stock-based compensation expense related to accelerated stock vesting at the IPO, as well as growth in billable headcount and performance-based employee compensation.

Total operating expenses for the fourth quarter of 2020 were $83.3 million, an increase from $27.9 million in the fourth quarter of 2019, primarily due to a $53.1 million increase in stock-based compensation expense related to accelerated stock vesting at the IPO.

Net loss for the fourth quarter of 2020 was ($54.4) million, an increase from ($6.0) million of net loss in the fourth quarter of 2019, primarily due to a $61.6 million increase in stock-based compensation expense related to accelerated stock vesting at the IPO. Diluted Earnings Per Share for the fourth quarter 2020 was ($0.40) compared to ($0.05) for the fourth quarter of 2019.

Adjusted EBITDA for the fourth quarter of 2020 was $22.2 million compared to $16.3 million for the fourth quarter of 2019.

Adjusted Net Income for the fourth quarter of 2020 was $11.8 million compared to an Adjusted Net Loss of ($3.7) million for the fourth quarter of 2019. Adjusted Diluted Earnings Per Share for the fourth quarter 2020 was $0.09 compared to ($0.03) for the fourth quarter of 2019. See note (2) in the section A Note on Non-GAAP Financial Measures, below, for more information on Adjusted Net Income and Adjusted Diluted Earnings Per Share.

Full Year 2020 Results

Total revenue for the full year ended December 31, 2020 was $243.5 million, representing 17% growth over 2019. The revenue growth was driven by growth in our technology enabled services and software product offerings due to strong renewal rates and client expansions.

Total cost of revenues for the full year of 2020 was $100.8 million, an increase from $79.8 million for the full year of 2019, primarily due to increased billable headcount, performance-based employee compensation and an $8.6 million increase in stock-based compensation expense primarily due to accelerated vesting relating to the IPO.

Total operating expenses for the full year of 2020 were $167.2 million, an increase from $109.1 million for the full year of 2019, primarily due to a $54.2 million increase in stock-based compensation expense related to accelerated stock vesting at the IPO.

Net loss for the full year of 2020 was ($49.4) million, an increase from ($8.9) million of net loss in the full year of 2019. This was primarily due to a $62.8 million increase in stock-based compensation expense related to accelerated stock vesting at the IPO. Diluted Earnings Per Share for the full year 2020 was ($0.37) compared to ($0.07) for the full year of 2019.

Adjusted EBITDA for the full year 2020 was $87.9 million compared to $68.4 million for 2019.

Adjusted Net Income for the full year 2020 was $22.0 million compared to $0.8 million for 2019. Adjusted Diluted Earnings Per Share for 2020 was $0.17 compared to $0.01 for 2019.

Cash and cash equivalents were $271.4 million as of December 31, 2020, and total debt outstanding net of debt issuance costs was $298.8 million after the voluntary repayment of $80 million of long-term debt in the fourth quarter. The current debt structure does not include any significant maturity until 2024.

Three Months Ended
December 31,

Year Ended
December 31,

2020

2019

2020

2019

Key Financials (in millions, except per share data)

Revenue

$64.6

$53.9

$243.5

$208.5

Net Loss

($54.4

)

($6.0

)

($49.4

)

($8.9

)

Diluted Earnings Per Share

($0.40

)

($0.05

)

($0.37

)

($0.07

)

Adjusted EBITDA

$22.2

$16.3

$87.9

$68.4

Adjusted Net Income (Loss)

$11.8

($3.7

)

$22.0

$0.8

Adjusted Diluted Earnings Per Share

$0.09

($0.03

)

$0.17

$0.01

Cash and Cash Equivalents

$271.4

$29.3

2021 Financial Outlook

Certara expects full year 2021 revenue to be in the range of $272 million to $285 million.

Certara expects full year 2021 Adjusted EBITDA to be in the range of $98 million to $102 million.

Full year 2021 Adjusted Diluted Earnings Per Share is expected to be in the range of $0.20 to $0.24.

The expected fully diluted shares for 2021 will be 153 million to 155 million.

The expected effective tax rate for 2021 will be 45% to 50%.

In millions, except per share data

Full Year 2021 (Range)

Revenue

$272 - $285

Adjusted EBITDA

$98 - $102

Adjusted Diluted Earnings Per Share

$0.20 - $0.24

Webcast and Conference Call Details

Certara will host a conference call today, March 4, 2021, at 5:00 p.m. ET to discuss its full year and fourth quarter 2020 financial results. The dial-in numbers are (833) 360-0946 for domestic callers or (914) 987-7661 for international callers, followed by Conference ID: 6546156. A live webcast of the conference call will be available on the "Investors" section of the Company's website at https://ir.certara.com/. The webcast will be archived on the website following the completion of the call for approximately one year.

About Certara

Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Please visit our website at www.certara.com. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in the Investor Relations section of our website at https://ir.certara.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, Securities and Exchange Commission filings and public conference calls and webcasts.

Forward-Looking Statements

This press release contains certain statements that constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, with respect to the Company’s future business and financial performance and earnings per share. These statements typically contain words such as "believe," "may," "potential," "will," "plan," "could," "estimate," "expects" and "anticipates" or the negative of these words or other similar terms or expressions. Any statement in this press release that is not a statement of historical fact is a forward-looking statement and involves significant risks and uncertainties. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot provide any assurance that these expectations will prove to be correct. You should not rely upon forward-looking statements as predictions of future events and actual results, events, or circumstances. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the Company’s ability to compete within its market; any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery; changes or delays in relevant government regulation; increasing competition, regulation and other cost pressures within the pharmaceutical and biotechnology industries; trends in research and development (R&D) spending; consolidation within the biopharmaceutical industry; reduction in the use of the Company’s products by academic institutions; pricing pressures; the Company’s ability to successfully enter new markets, increase its customer base and expand its relationships with existing customers; the occurrence of natural disasters and epidemic diseases, such as the recent COVID-19 pandemic; any delays or defects in the release of new or enhanced software or other biosimulation tools; failure of its existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by its existing customers; its ability to accurately estimate costs associated with its fixed-fee contracts; its ability to retain key personnel or recruit additional qualified personnel; risks related to our contracts with government customers; its ability to sustain recent growth rates; any future acquisitions and its ability to successfully integrate such acquisitions; its ability to successfully operate a global business; its ability to comply with applicable laws and regulations; risks related to litigation; the adequacy of its insurance coverage and ability to obtain adequate insurance coverage in the future; its ability to perform in accordance with contractual requirements, regulatory standards and ethical considerations; the loss of more than one of its major customers; its future capital needs; the ability of its bookings to accurately predict future revenue and its ability to realize revenue on backlog; disruptions in the operations of the third-party providers who host its software solutions or any limitations on their capacity; its ability to reliably meet data storage and management requirements, or the experience of any failures or interruptions in the delivery of its services over the internet; its ability to comply with the terms of any licenses governing use of third-party open source software; any breach of its security measures or unauthorized access to customer data; its ability to adequately enforce or defend ownership and use of its intellectual property and other proprietary rights; ​any allegations of infringement, misappropriation or violations of a third party’s intellectual property rights; its ability to meet obligations under indebtedness and have sufficient capital to operate its business; any limitations on its ability to pursue business strategies due to restrictions under our current or future indebtedness; any impairment of goodwill or other intangible assets; its ability to use its net operating losses and R&D tax credit carryforwards; the accuracy of management’s estimates and judgments relating to critical accounting policies and changes in financial reporting standards or interpretations; actions by its controlling stockholders; any inability to design, implement, and maintain effective internal controls; the costs and management time associated with operating as a publicly traded company; and the other factors detailed under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" and elsewhere in our Securities and Exchange Commission ("SEC") filings, and reports, including the prospectus filed by the Company with the Securities and Exchange Commission on December 14, 2020. Any forward-looking statements speak only as of the date of this release and, except to the extent required by applicable securities laws, we expressly disclaim any obligation to update or revise any of them to reflect actual results, any changes in expectations or any change in events. Factors that may materially affect our results and those risks listed in filings with the SEC.

A Note on Non-GAAP Financial Measures

This press release contains "non-GAAP measures" that are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles ("GAAP"). Specifically, the Company makes use of the non-GAAP financial measures Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Diluted Earnings Per Share which are not recognized terms under GAAP and should not be considered as alternatives to net income (loss) or GAAP diluted earnings per share as measures of financial performance or any other performance measure derived in accordance with GAAP and should not be considered a measure of discretionary cash available to the Company to invest in the growth of its business. The presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the Company’s results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

You should refer to the footnotes below as well as the "Non-GAAP Financial Measures" section in this press release below for a further explanation of these measures and reconciliations of these non-GAAP measures in specific periods to their most directly comparable financial measure calculated and presented in accordance with GAAP for those periods.

Management uses various financial metrics, including total revenues, income (loss) from operations, net income (loss), and certain non-GAAP measures, including those discussed above, to measure and assess the performance of the Company’s business, to evaluate the effectiveness of its business strategies, to make budgeting decisions, to make certain compensation decisions, and to compare the Company’s performance against that of other peer companies using similar measures. In addition, management believes these metrics provide useful measures for period-to-period comparisons of the Company’s business, as they remove the effect of certain non-cash expenses and other items not indicative of its ongoing operating performance.

Management believes that Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Diluted Earnings Per Share are helpful to investors, analysts, and other interested parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, these measures are frequently used by analysts, investors, and other interested parties to evaluate and assess performance.

Please note that the Company has not reconciled the Adjusted EBITDA, and Adjusted Diluted Earnings Per Share forward-looking guidance included in this press release to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to costs related to acquisitions, financings, and employee stock compensation programs, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.

(1)

Adjusted EBITDA represents net income (loss) excluding interest expense, provision (benefit) for income taxes, depreciation and amortization expense, intangible asset amortization, equity-based compensation expense, acquisition and integration expense and other items not indicative of our ongoing operating performance.

(2)

Adjusted Net Income (Loss) and Adjusted Diluted Earnings Per Share exclude the effect of the items discussed in footnote (1) above from GAAP net income (loss) and GAAP diluted earnings per share, respectively, as well as currency gain (loss) and adjust the provision for income taxes for such charges.

In evaluating Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Diluted Earnings Per Share, you should be aware that in the future the Company may incur expenses similar to those eliminated in this presentation and this presentation should not be construed as an inference that future results will be unaffected by unusual items.

CERTARA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

THREE MONTHS ENDED
DECEMBER 31,

YEAR ENDED
DECEMBER 31,

(in thousands, except per common share and share data)

2020

2019

2020

2019

Revenue

$64,641

$53,857

$243,530

$208,511

Cost of revenues

34,905

21,953

100,765

79,770

Operating expenses:

Sales and marketing

10,429

2,786

19,202

10,732

Research and development

10,505

2,982

19,644

11,633

General and administrative

52,357

12,296

88,482

47,926

Intangible asset amortization

9,358

9,333

37,414

36,241

Depreciation and amortization expense

607

456

2,443

2,596

Total operating expenses

83,256

27,853

167,185

109,128

Income (loss) from operations

(53,520

)

4,051

(24,420

)

19,613

Other revenue (expenses):

Interest expense, net

(5,486

)

(6,993

)

(25,296

)

(28,004

)

Miscellaneous, net

(921

)

(597

)

(465

)

(760

)

Total other revenue (expenses)

(6,407

)

(7,590

)

(25,761

)

(28,764

)

Loss before income taxes

(59,927

)

(3,539

)

(50,181

)

(9,151

)

(Benefit from) provision for income taxes

(5,480

)

2,476

(784

)

(225

)

Net loss

($54,447

)

($6,015

)

($49,397

)

($8,926

)

Net loss per common share – basic and diluted

($0.40

)

($0.05

)

($0.37

)

($0.07

)

Basic and diluted weighted average common shares outstanding

135,747,243

132,407,786

133,247,212

132,407,786

CERTARA, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

AS OF
DECEMBER 31,

(in thousands, except per common share and share data)

2020

2019

Assets

Current assets:

Cash and cash equivalents

$271,382

$29,256

Accounts receivable, net of allowance for doubtful accounts of $132 and $185, respectively

54,091

49,642

Restricted cash

1,909

506

Prepaid expenses and other current assets

19,202

8,119

Total current assets

346,584

87,523

Other assets:

Property and equipment, net

3,872

4,623

Long-term deposits

1,163

1,096

Goodwill

518,592

514,996

Intangible assets, net of accumulated amortization of $127,172 and $85,925, respectively

396,445

427,998

Deferred income taxes

2,744

833

Total assets

$1,269,400

$1,037,069

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$6,394

$4,917

Accrued expenses

30,729

27,036

Current portion of deferred revenue

30,662

26,240

Current portion of interest rate swap liability

2,605

551

Current portion of long-term debt

4,680

4,210

Current portion of capital lease obligations

275

48

Total current liabilities

75,345

63,002

Long-term liabilities:

Capital lease obligations, net of current portion

318

-

Deferred revenue, net of current portion

545

1,137

Deferred income taxes

75,894

82,160

Long-term portion of interest rate swap liability

1,066

1,601

Long-term debt, net of current portion and debt discount

294,100

397,121

Total liabilities

447,268

545,021

Commitments and contingencies

Stockholders' equity

Preferred shares, $0.01 par value, 50,000,000 and 0 shares authorized as of December 31, 2020 and 2019, respectively, 0 shares issued and outstanding as of December 31, 2020 and 2019, respectively

Common shares, $0.01 par value, 600,000,000 shares authorized, 152,979,479 and 132,407,786 shares issued and outstanding as of December 31, 2020 and 2019, respectively

1,529

1,324

Additional paid-in capital

884,528

509,162

Accumulated deficit

(62,338

)

(12,941

)

Accumulated other comprehensive loss

(1,587

)

(5,497

)

Total stockholders' equity

822,132

492,048

Total liabilities and stockholders' equity

$1,269,400

$1,037,069

CERTARA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

YEAR ENDED
DECEMBER 31,

(in thousands)

2020

2019

Cash flows from operating activities:

Net loss

($49,397

)

($8,926

)

Adjustments to reconcile net loss to net cash provided by operating activities:

Depreciation and amortization of property and equipment

2,443

2,596

Amortization of intangible assets

40,310

38,964

Amortization of debt issuance costs

1,520

1,536

Provision for doubtful accounts

(53

)

10

Loss on retirement of assets

19

113

Equity compensation expense

64,507

1,691

Deferred income taxes

(7,825

)

(6,703

)

Changes in assets and liabilities, net of acquisitions:

Accounts receivable

(3,932

)

(1,521

)

Prepaid expenses and other assets

(8,257

)

(1,831

)

Accounts payable and accrued expenses

2,381

10,031

Deferred revenue

3,094

2,065

Net cash provided by operating activities

44,810

38,025

Cash flows from investing activities:

Capital expenditures

(863

)

(2,107

)

Capitalized development costs

(7,074

)

(7,410

)

Business acquisitions, net of cash acquired

(675

)

-

Net cash used in investing activities

(8,612

)

(9,517

)

Cash flows from financing activities:

Capital contributions

250

650

Unit repurchase

(1,079

)

(703

)

Proceeds from issuance of common stock upon initial public offering, net of underwriters’ discounts and commissions

316,301

-

Payments on long-term debt and capital lease obligations

(104,358

)

(3,436

)

Proceeds on line of credit

19,880

-

Payments from line of credit

(19,880

)

(5,000

)

Payments of deferred offering costs

(2,900

)

-

Net cash provided by (used in) financing activities

208,214

(8,489

)

Effect due to foreign exchange rate changes on cash, cash equivalents, and restricted cash

(883

)

(2,444

)

Net increase in cash, cash equivalents, and restricted cash

243,529

17,575

Cash, cash equivalents, and restricted cash, at beginning of year

29,762

12,187

Cash, cash equivalents, and restricted cash, at end of year

$273,291

$29,762

NON-GAAP FINANCIAL MEASURES

The following table reconciles Net loss to Adjusted EBITDA:

THREE MONTHS ENDED
DECEMBER 31,

YEAR ENDED
DECEMBER 31,

(in thousands)

2020

2019

2020

2019

Net loss

($54,447

)

($6,015

)

($49,397

)

($8,926

)

Interest expense(a)

5,486

6,993

25,296

28,004

Interest income(a)

(8

)

(3

)

(44

)

(9

)

(Benefit from) provision for income taxes(a)

(5,480

)

2,476

(784

)

(225

)

Depreciation and amortization expense(a)

607

456

2,443

2,596

Intangible asset amortization(a)

10,506

10,459

40,310

38,964

Currency loss(a)

905

353

715

431

Equity-based compensation expense(b)

62,221

550

64,507

1,691

Acquisition-related expense(c)

291

477

1,456

2,471

Integration expense(d)

21

45

78

546

Transaction related expenses(e)

1,421

-

1,908

-

Severance expense(f)

196

125

557

2,057

Reorganization expense(g)

335

50

525

222

Loss on disposal of fixed assets(h)

10

103

19

113

Executive recruiting expense(i)

100

186

288

476

Adjusted EBITDA

$22,164

$16,255

$87,877

$68,411

The following table reconciles Net loss to Adjusted Net Income (Loss):

THREE MONTHS ENDED
DECEMBER 31,

YEAR ENDED
DECEMBER 31,

(in thousands, except per share data)

2020

2019

2020

2019

Net loss

($54,447

)

($6,015

)

($49,397

)

($8,926

)

Currency loss(a)

905

353

715

431

Equity-based compensation expense(b)

62,221

550

64,507

1,691

Acquisition-related expense(c)

291

477

1,456

2,471

Integration expense(d)

21

45

78

546

Transaction related expenses(e)

1,421

-

1,908

-

Severance expense(f)

196

125

557

2,057

Reorganization expense(g)

335

50

525

222

Loss on disposal of fixed assets(h)

10

103

19

113

Executive recruiting expense(i)

100

186

288

476

Income tax expense impact of adjustments(j)

781

406

1,381

1,758

Adjusted Net Income (Loss)

$11,834

($3,720

)

$22,037

$839

The following table reconciles diluted earnings per share to Adjusted Diluted Earnings Per Share:

THREE MONTHS ENDED
DECEMBER 31,

YEAR ENDED
DECEMBER 31,

2020

2019

2020

2019

Diluted earnings per share

($0.40

)

($0.05

)

($0.37

)

($0.07

)

Currency loss(a)

0.01

-

0.01

-

Equity-based compensation expense(b)

0.46

0.01

0.48

0.01

Acquisition-related expense(c)

-

0.01

0.01

0.02

Integration expense(d)

-

-

-

0.01

Transaction related expenses(e)

0.01

-

0.01

-

Severance expense(f)

-

-

0.01

0.02

Reorganization expense(g)

-

-

0.01

-

Loss on disposal of fixed assets(h)

-

-

-

-

Executive recruiting expense(i)

-

-

-

0.01

Income tax expense impact of adjustments(j)

0.01

-

0.01

0.01

Effect of using adjusted diluted shares(k)

-

-

-

-

Adjusted Diluted Earnings Per Share

$0.09

($0.03

)

$0.17

$0.01

Diluted weighted average common shares outstanding

135,747,243

132,407,786

133,247,212

132,407,786

Effect of potentially dilutive shares outstanding(l)

912,544

-

229,383

-

Adjusted diluted weighted average common shares outstanding

136,659,787

132,407,786

133,476,595

132,407,786

(a)

Represents amounts as determined under GAAP.

(b)

Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.

(c)

Represents costs associated with mergers and acquisitions and any retention bonuses pursuant to the acquisitions.

(d)

Represents integration costs related to post-acquisition integration activities.

(e)

Represents costs associated with our initial public offering that are not capitalized.

(f)

Represents charges for severance provided to former executives and non-executives.

(g)

Represents expense related to reorganization, including legal entity reorganization.

(h)

Represents the gain/loss related to disposal of fixed assets.

(i)

Represents recruiting and relocation expenses related to hiring a CEO and other senior executives.

(j)

Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction.

(k)

Represents the effect of using the Adjusted diluted weighted average common shares outstanding.

(l)

Represents potentially dilutive shares that were excluded from the Company’s GAAP diluted weighted average shares outstanding because the Company had a reported net loss and therefore including these shares would have been anti-dilutive.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210304006041/en/

Contacts

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com